the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.
Company profile
Ticker
DNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Acorda Therapeutics • Exelixis ...
Former names
Soaring Eagle Acquisition Corp., Spinning Eagle Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Ginkgo Bioworks, Inc. • Ginkgo Bioworks Securities Corporation • Concentric by Ginkgo, LLC • Ginkgo International Holdings, Inc. • Concentric Consultancy QFZ LLC ...
DNA stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
14 Mar 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
8-K
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
10 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Oct 23
8-K
Other Events
3 Oct 23
EFFECT
Notice of effectiveness
30 Aug 23
Transcripts
DNA
Earnings call transcript
2023 Q3
8 Nov 23
DNA
Earnings call transcript
2023 Q2
9 Aug 23
DNA
Earnings call transcript
2023 Q1
10 May 23
DNA
Earnings call transcript
2022 Q4
1 Mar 23
DNA
Earnings call transcript
2022 Q3
15 Nov 22
DNA
Earnings call transcript
2022 Q2
16 Aug 22
DNA
Earnings call transcript
2022 Q1
17 May 22
DNA
Earnings call transcript
2021 Q4
29 Mar 22
DNA
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn |
Cash burn (monthly) | 25.81 mm | 20.91 mm | 100.97 mm | 77.81 mm | 24.52 mm | 28.52 mm |
Cash used (since last report) | 171.96 mm | 139.27 mm | 672.61 mm | 518.30 mm | 163.32 mm | 189.96 mm |
Cash remaining | 922.66 mm | 955.34 mm | 422.01 mm | 576.32 mm | 931.30 mm | 904.66 mm |
Runway (months of cash) | 35.7 | 45.7 | 4.2 | 7.4 | 38.0 | 31.7 |
Institutional ownership, Q3 2023
82.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 337 |
Opened positions | 59 |
Closed positions | 24 |
Increased positions | 135 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 2.20 tn |
Total shares | 1.37 bn |
Total puts | 2.93 mm |
Total calls | 2.48 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 238.81 mm | $432.24 bn |
ARK Investment Management | 182.19 mm | $329.77 bn |
Cascade Investment, L.L.C. | 151.87 mm | $1.73 bn |
Viking Global Investors | 143.09 mm | $258.98 bn |
Vanguard | 132.32 mm | $239.49 bn |
BLK Blackrock | 72.70 mm | $131.59 bn |
Anchorage Capital Group, L.L.C. | 69.85 mm | $126.44 bn |
CMTDF Sumitomo Mitsui Trust | 58.75 mm | $106.33 bn |
Nikko Asset Management Americas | 58.75 mm | $106.33 bn |
MS Morgan Stanley | 49.77 mm | $90.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Mark E. Dmytruk | Class A Common Stock | Sell | Dispose S | No | No | 1.05 | 51,169 | 53.73 k | 865,079 |
1 Apr 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,634 | 0.00 | 916,248 |
1 Apr 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 22,916 | 0.00 | 914,614 |
1 Apr 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 18,125 | 0.00 | 891,698 |
1 Apr 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 65,448 | 0.00 | 873,573 |
1 Apr 24 | Mark E. Dmytruk | Class B Common Stock Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 1,634 | 0.00 | 628,685 |
1 Apr 24 | Mark E. Dmytruk | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 22,916 | 0.00 | 1,077,084 |
1 Apr 24 | Mark E. Dmytruk | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 18,125 | 0.00 | 634,375 |
1 Apr 24 | Mark E. Dmytruk | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 65,448 | 0.00 | 712,436 |
7 Mar 24 | Steven P. Coen | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 300,000 | 0.00 | 300,000 |
News
Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM® Technology
12 Apr 24
What's Going On With Ginkgo Bioworks Stock?
11 Apr 24
Ginkgo Bioworks Reports Acquisition Of AgBiome's Platform Assets
11 Apr 24
IdeeLab Biotechnology Enters Agreement With Ginkgo Bioworks To Join Ginkgo Technology Network
8 Apr 24
Ginkgo Bioworks Acquired Modulus Therapeutics' Cell Therapy Assets; Terms Not Disclosed
2 Apr 24
Press releases
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
16 Apr 24
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
11 Apr 24
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
11 Apr 24
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
10 Apr 24
Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks
10 Apr 24